Cargando…

Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review

BACKGROUND: Preoperative treatment is performed for locally advanced colon cancer with extensive tumor proximity or suspected invasion of skeletal muscles, major organs, and blood vessels. Oxaliplatin-based regimens are often used in preoperative chemotherapy. However, microsatellite instability (MS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawayama, Hiroshi, Miyamoto, Yuji, Ogawa, Katsuhiro, Ohuchi, Mayuko, Hisano, Yuki, Kato, Moeko, Tubakihara, Hiroki, Yoshida, Naoya, Baba, Hideo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794638/ https://www.ncbi.nlm.nih.gov/pubmed/36574162 http://dx.doi.org/10.1186/s40792-022-01580-w

Ejemplares similares

Investigation of colorectal cancer in accordance with consensus molecular subtype classification
por: Sawayama, Hiroshi, et al.
Publicado: (2020)

Emerging evidence of immunotherapy for colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2022)

Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Rectal cancer diagnosed after resection of isolated brain metastasis
por: Tagayasu, Yoshiyuki, et al.
Publicado: (2022)

Repeated intestinal perforations in vascular Ehlers-Danlos syndrome: a case report of a novel mutation in the COL3A1 gene
por: Horino, Taichi, et al.
Publicado: (2023)

Essential updates 2020/2021: Colorectal diseases (benign)—Current topics in the surgical and medical treatment of benign colorectal diseases
por: Sawayama, Hiroshi, et al.
Publicado: (2022)

Overall survival after recurrence in stage I–III colorectal cancer patients in accordance with the recurrence organ site and pattern
por: Sawayama, Hiroshi, et al.
Publicado: (2021)

A case of clinical stage I gastric cancer with a schwannoma on the left supraclavicular fossa suspected as Virchow’s node metastasis
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Evaluation of clinical outcomes with propensity‐score matching for colorectal cancer presenting as an oncologic emergency
por: Ogawa, Katsuhiro, et al.
Publicado: (2022)

Laparoscopic surgery for colorectal cancer with persistent descending mesocolon
por: Hiyoshi, Yukiharu, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review
por: Gim, Gahyun, et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer
por: Miyamoto, Yuji, et al.
Publicado: (2015)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Primary colonic well-differentiated / dedifferentiated liposarcoma of the ascending colon: a case report
por: Sawayama, Hiroshi, et al.
Publicado: (2017)

Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer
por: Sawayama, Hiroshi, et al.
Publicado: (2019)

Activin A promotes cell proliferation, invasion and migration and predicts poor prognosis in patients with colorectal cancer
por: Daitoku, Nobuya, et al.
Publicado: (2022)

Preoperative skeletal muscle status is associated with tumor‐infiltrating lymphocytes and prognosis in patients with colorectal cancer
por: Daitoku, Nobuya, et al.
Publicado: (2022)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
por: Nakamura, Mikako, et al.
Publicado: (2023)

PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
por: Okadome, Kazuo, et al.
Publicado: (2021)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
por: Segawa, Takuya, et al.
Publicado: (2023)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Preoperative transferrin level is a novel prognostic marker for colorectal cancer
por: Sawayama, Hiroshi, et al.
Publicado: (2021)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3gnqj9vdsaa7k9raqc5o9kv6oc